The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte And Regeneron Pharmaceuticals
Zacks Investment Research | Nov 19, 2019 09:50PM ET
For Immediate Release
Chicago, IL – November 20, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alexion Pharmaceuticals, Inc.’s (NASDAQ:ALXN) , Vertex Pharmaceuticals Inc.’s (NASDAQ:VRTX) , Incyte Corporation (NASDAQ:INCY) and Regeneron Pharmaceuticals (NASDAQ:REGN) .
Here are highlights from Tuesday’s Analyst Blog:
4 Big Biotech Stocks Worth Considering Post-Q3 Earnings
The third-quarter earnings season was pretty impressive for the biotech sector as quite a few companies beat on both the top- and the bottom line as well as raised their annual outlook. Biotech majors like Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) delivered a comprehensive beat. Celgene (NASDAQ:CELG), which is slated to be acquired by Bristol-Myers Squibb (NYSE:BMY) shortly, also fired on all cylinders owing to strong sales growth. Meanwhile, Gilead (NASDAQ:GILD) missed on earnings but beat on sales.
Nevertheless, the quarterly performance of this risk-prone biotech sector was decent as new drug approvals, label expansions of blockbuster drugs and encouraging pipeline updates drove growth for quite a few stocks this reporting cycle.
It has been a roller-coaster ride for the volatile biotech sector so far this year. While 2019 started with a bang announcing the mega merger between Bristol-Myers and Celgene that significantly perked up prices of quite a few stocks, these gains were partially offset gradually, primarily due to the overall weakness in the global market. The recent series of consolidations is expected to continue as well with both big biotech and small biotech stocks, which have a dominant position in the lesser competitive arena of rare diseases and NASH and are well-equipped with path-breaking technology, respectively.
As fears of a global recession persist to spook investors, the inherent peril of the sector gets intensified. In such a scenario, choosing a biotech stock for investment can be tricky. Particularly, smaller biotechs are more hazardous as their product pipelines are several years away from commercialization. In contrast, investing in biotech biggies provides a cushion against volatility in the sector. Moreover, the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.